文献速递头颈与中枢神经肿瘤

循环肿瘤DNA辅助PET-CT判断头颈癌治疗后的临床结局

Circulating tumour DNA to augment PET-CT in determining clinical outcome after head and neck cancer treatment.
PubMed 文献 · Eur J Cancer · 2025-07-10

本研究纳入41例接受放化疗或手术的头颈癌患者,于治疗前及治疗后10-12周同步进行液体活检与影像学检查,评估循环肿瘤DNA能否辅助治疗后的决策。放化疗患者中PET-CT有13/27例结果不明确,液体活检判断真实疾病状态的灵敏度和特异度分别为83%和95%,优于PET-CT的67%和42%;液体活检联合影像的灵敏度和特异度达100%和90%,特异度改善有统计学意义。

要点

  • 放化疗患者中PET-CT有13/27例结果不明确,判断真实疾病状态的灵敏度67%、特异度42%。
  • 液体活检判断真实疾病状态的灵敏度83%、特异度95%,优于PET-CT。
  • 液体活检联合PET/MRI的灵敏度100%、特异度90%,特异度改善有统计学意义。

核心结论

  • 液体活检在判断放化疗后真实疾病状态方面优于PET-CT,可能辅助放化疗及手术患者治疗后的影像评估,并可能在治疗后决策中发挥作用。

研究设计与样本

  • 研究纳入41例接受放化疗和手术治疗的头颈癌患者,于治疗前及治疗后10-12周进行系列血液检测并同步影像学检查。
  • PET-CT/MRI结果分为癌症、不明确和完全缓解三类,真实疾病状态通过回顾性方式确定。
  • ctDNA检测采用定制的17基因 panel 和靶向5种HPV亚型的探针进行二代测序。

主要发现

  • 放化疗患者中PET-CT有13/27例结果不明确,判断真实疾病状态的灵敏度为67%、特异度为42%。
  • 放化疗患者治疗后液体活检判断真实疾病状态的灵敏度为83%、特异度为95%,优于PET-CT。
  • 液体活检联合PET/MRI判断真实疾病状态的灵敏度为100%、特异度为90%,优于单独影像学检查。
  • 联合检测特异度改善有统计学意义(Fisher精确检验 OR=7.1;95%CI:1.6-45.8,P=0.0005),平衡准确率改善亦有统计学意义(Welch t检验,P<0.0001)。

局限性

  • 真实疾病状态通过回顾性方式确定。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIM: PET-CT and MRI are used to assess disease response after head and neck cancer treatment. Equivocal findings can delay the potential for salvage curative treatment or result in over- treatment with further surgery. The aims of this study were to establish if liquid biopsy (LB) of circulating tumour DNA, could be used to aid decision-making after treatment. METHOD: Patients (n = 41) undergoing chemoradiotherapy (CRT) and surgical treatment had serial blood testing; pre-treatment and 10-12 weeks post-treatment, alongside imaging. PET-CT/MRIs were categorised as Cancer, Equivocal or Complete Response and true disease status was determined retrospectively. A bespoke 17-gene panel and probes targeting 5 HPV subtypes were used for next-generation sequencing in the ctDNA assay. RESULTS: PET-CT was equivocal in 13/27 CRT patients; sensitivity and specificity for determining true disease status was 67 % and 42 % respectively. LB performed better at determining true disease status than PET-CT post-treatment in CRT patients; sensitivity and specificity of 83 % and 95 % respectively. A combined LB/PET/MRI test performed better than imaging alone; sensitivity and specificity of 100 % and 90 % respectively. The improved specificity was statistically significant (Fisher's exact test OR=7.1; 95 % CI:1.6-45.8, p = 0.0005), as was the balanced accuracy (Welch's t-test, p < 0.0001). CONCLUSION: LB outperformed PET-CT at determining true disease status after CRT and could complement post-treatment imaging in CRT and surgical patients, playing a potential role in decision-making after treatment.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Bola S, Cutts A, Vavoulis D, et al. Circulating tumour DNA to augment PET-CT in determining clinical outcome after head and neck cancer treatment. Eur J Cancer. 2025. PMID: 40706443. doi:10.1016/j.ejca.2025.115626

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。